These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26644118)

  • 1. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.
    Wright E; Schofield PT; Molokhia M
    BMJ Open; 2015 Dec; 5(12):e007133. PubMed ID: 26644118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).
    Wright E; Schofield PT; Seed P; Molokhia M
    PLoS One; 2012; 7(10):e47616. PubMed ID: 23112825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.
    Sun K; Liu JM; Sun HX; Lu N; Ning G
    Osteoporos Int; 2013 Jan; 24(1):279-86. PubMed ID: 23052941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to oral bisphosphonates and risk of esophageal cancer.
    Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
    JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
    Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
    PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
    Oh YH; Yoon C; Park SM
    World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal and gastric cancer incidence and mortality in alendronate users.
    Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
    J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and risk of lung cancer: Protocol for a systematic review and meta-analysis.
    Li M; Zhong M; Guan C
    Medicine (Baltimore); 2021 Jan; 100(1):e22839. PubMed ID: 33429726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2013 Jan; 346():f114. PubMed ID: 23325866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer.
    Haber SL; McNatty D
    Ann Pharmacother; 2012 Mar; 46(3):419-23. PubMed ID: 22333262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies.
    Cai D; Qin J; Chen G; Feng W; Liu J
    Minerva Med; 2017 Oct; 108(5):464-472. PubMed ID: 28466630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
    Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V
    BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
    Loke YK; Jeevanantham V; Singh S
    Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More on reports of esophageal cancer with oral bisphosphonate use.
    Shaheen NJ
    N Engl J Med; 2009 Apr; 360(17):1790-1; author reply 1791-2. PubMed ID: 19391257
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
    Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
    Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
    Andrici J; Tio M; Eslick GD
    Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.